Vivos Therapeutics FY2025 revenue up 16% to $17.5M; operating loss widens to $19.9M

Vivos Therapeutics, Inc.

FY2025 revenue $17.5M, +16% YoY from $15.0M; driven by sleep testing services and SCN acquisition.
Operating loss $19.9M vs $11.2M in FY2024; expenses rose to $30.4M on SCN integration costs.
Cash and equivalents $2.0M at Dec. 31, 2025; subsequent financing raised $6.8M in gross proceeds.
Gross margin held at 60%; business pivoting from VIP enrollment to sleep provider acquisitions and alliances.
Management targets achieving cash-flow-positive operations by end of 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vivos Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $17.5 million.

Period: the full year ended December 31, 2025
Revenue: $17.5 million
Result: reported results

Exact text from the filing

Revenue was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year over year increase of 16%.

View on SEC.gov

1347 earnings releases filed in the last 30 days. Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-016865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.